English

ACCELERON PHARMA INC.

EDGAR

XLRN Quarterly report (10-Q) · filed 2021-11-04

86 filing records in this dataset, filed from 2013-08-07 to 2021-11-04. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

34.2 million USD

2021 Q3 · USD

Exact inputs and evidence

Revenue: 34199000 USD Source

Operating margin

-206.53%

2021 Q3 · %

Exact inputs and evidence

Operating Income: -70630000 USD Source
Revenue: 34199000 USD Source

Operating cash flow

-70.9 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -223227000 USD Source
Operating Cash Flow: -152339000 USD Source

Free cash flow

-73.3 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -223227000 USD Source
Operating Cash Flow: -152339000 USD Source
Capital Expenditure: 4298000 USD Source
Capital Expenditure: 1889000 USD Source

Cash and cash equivalents: 336 million USD 2021-09-30 Source
Exact value

336456000 USD
Long-term debt including current maturities: 20 million USD 2012-12-31 Source
Exact value

20000000 USD
Shares outstanding: 61.1 million shares 2021-09-30 Source
Exact value

61130687 shares

Reported share-count change

1.80% · 1.08 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

60052046 shares · 2020-09-30· Source
61130687 shares · 2021-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

113 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Revenue: 25866000 USD · 2020-10-01 – 2020-12-31 Source
Revenue: 24758000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 27940000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 34199000 USD · 2021-07-01 – 2021-09-30 Source

Net income

-255 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Net income: -57396000 USD · 2020-10-01 – 2020-12-31 Source
Net income: -63471000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -63521000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -70465000 USD · 2021-07-01 – 2021-09-30 Source

Operating cash flow

-261 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Operating cash flow: -130327000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -92197000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -67924000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -152339000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -67924000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -223227000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -152339000 USD · 2021-01-01 – 2021-06-30 Source

Capital expenditure

5.2 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Capital expenditure: 4203000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 3303000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 920000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 1889000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 920000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 4298000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 1889000 USD · 2021-01-01 – 2021-06-30 Source

Free cash flow

-267 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Operating cash flow: -130327000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -92197000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -67924000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -152339000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -67924000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -223227000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -152339000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 4203000 USD · 2020-01-01 – 2020-12-31 Source
Capital expenditure: 3303000 USD · 2020-01-01 – 2020-09-30 Source
Capital expenditure: 920000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 1889000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 920000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 4298000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 1889000 USD · 2021-01-01 – 2021-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-11-04.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2020-12-31
Operating income: 10 of 11 periods available· newest 2020-12-31
Net income: 10 of 11 periods available· newest 2020-12-31
Operating cash flow: 10 of 11 periods available· newest 2020-12-31
Capital expenditure: 10 of 11 periods available· newest 2020-12-31
Total assets: 10 of 11 periods available· newest 2020-12-31
Total liabilities: 10 of 11 periods available· newest 2020-12-31
Current assets: 10 of 11 periods available· newest 2020-12-31
Current liabilities: 10 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2020-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2012-12-31
Shares outstanding: 10 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+25%

Prior period

USD 73.99 million

2019-01-01 – 2019-12-31
Current period

USD 92.52 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

92523000 − 73993000 = 18530000 USD

73993000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
92523000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Year-over-year change in Revenue: 18530000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 92523000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1091120 Filing: 000128060021000017 Input fundies:Revenue: 73993000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1092173 Filing: 000128060021000017
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 41.17 million

Prior period

−USD 124.86 million

2019-01-01 – 2019-12-31
Current period

−USD 166.03 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-166030000 − -124858000 = -41172000 USD

-124858000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-166030000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Year-over-year change in Net income: -41172000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -166030000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1290854 Filing: 000128060021000017 Input fundies:NetIncome: -124858000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1292024 Filing: 000128060021000017
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 36.52 million

Prior period

−USD 93.8 million

2019-01-01 – 2019-12-31
Current period

−USD 130.33 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-130327000 − -93804000 = -36523000 USD

-93804000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-130327000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Year-over-year change in Operating cash flow: -36523000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -130327000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1329139 Filing: 000128060021000017 Input fundies:OperatingCashFlow: -93804000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1330190 Filing: 000128060021000017
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+27.9%

Prior period

USD 3.29 million

2019-01-01 – 2019-12-31
Current period

USD 4.2 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

4203000 − 3287000 = 916000 USD

3287000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
4203000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Year-over-year change in Capital expenditure: 916000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4203000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1339929 Filing: 000128060021000017 Input fundies:CapitalExpenditure: 3287000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1340911 Filing: 000128060021000017
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 92.52 million 100% of revenue
Operating costs Derived USD 259.83 million 281% of revenue
Operating income −USD 167.31 million −181% of revenue
Tax, interest and other Derived −USD 1.28 million −1.4% of revenue
Net income −USD 166.03 million −179% of revenue

Cash

Operating cash flow −USD 130.33 million −141% of revenue
Capital expenditure USD 4.2 million 4.5% of revenue
Free cash flow Derived −USD 134.53 million −145% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2011 45%52%
2012 Operating loss: operating costs were 289% of revenue.
2013 Net loss: net income was −38% of revenue.
2014 Operating loss: operating costs were 479% of revenue.
2015 Operating loss: operating costs were 436% of revenue.
2016 Operating loss: operating costs were 338% of revenue.
2017 Operating loss: operating costs were 916% of revenue.
2018 Operating loss: operating costs were 989% of revenue.
2019 Operating loss: operating costs were 284% of revenue.
2020 Operating loss: operating costs were 281% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2011 2011-01-01 – 2011-12-31	80911000	42355000 Derived	38556000	2290000 Derived	36266000	9029000 Derived	Source 2011-01-01 – 2011-12-31: 80911000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: 38556000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: 36266000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: 9056000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 27000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	15254000	44143000 Derived	-28889000	3693000 Derived	-32582000	-39325000 Derived	Source 2012-01-01 – 2012-12-31: 15254000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -28889000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -32582000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -38884000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 441000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	57230000	50278000 Derived	6952000	28850000 Derived	-21898000	-19957000 Derived	Source 2013-01-01 – 2013-12-31: 57230000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: 6952000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -21898000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -19650000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 307000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	14632000	70096000 Derived	-55464000	-4205000 Derived	-51259000	-53734000 Derived	Source 2014-01-01 – 2014-12-31: 14632000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -55464000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -51259000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -53220000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 514000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	18097000	78976000 Derived	-60879000	3015000 Derived	-63894000	-45170000 Derived	Source 2015-01-01 – 2015-12-31: 18097000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -60879000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -63894000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -44211000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 959000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	27771000	93877000 Derived	-66106000	-9092000 Derived	-57014000	-47925000 Derived	Source 2016-01-01 – 2016-12-31: 27771000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -66106000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -57014000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -44545000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3380000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	13481000	123464000 Derived	-109983000	-1529000 Derived	-108454000	-80940000 Derived	Source 2017-01-01 – 2017-12-31: 13481000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -109983000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -108454000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -76544000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4396000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	13991000	138405000 Derived	-124414000	-5543000 Derived	-118871000	-97296000 Derived	Source 2018-01-01 – 2018-12-31: 13991000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -124414000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -118871000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -94706000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2590000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	73993000	210438000 Derived	-136445000	-11587000 Derived	-124858000	-97091000 Derived	Source 2019-01-01 – 2019-12-31: 73993000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -136445000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -124858000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -93804000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 3287000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	92523000	259829000 Derived	-167306000	-1276000 Derived	-166030000	-134530000 Derived	Source 2020-01-01 – 2020-12-31: 92523000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -167306000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -166030000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -130327000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 4203000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 92.5M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Revenue	80911000	Revenue: 80911000 Open source
20122012-12-31	Revenue	15254000	Revenue: 15254000 Open source
20132013-12-31	Revenue	57230000	Revenue: 57230000 Open source
20142014-12-31	Revenue	14632000	Revenue: 14632000 Open source
20152015-12-31	Revenue	18097000	Revenue: 18097000 Open source
20162016-12-31	Revenue	27771000	Revenue: 27771000 Open source
20172017-12-31	Revenue	13481000	Revenue: 13481000 Open source
20182018-12-31	Revenue	13991000	Revenue: 13991000 Open source
20192019-12-31	Revenue	73993000	Revenue: 73993000 Open source
20202020-12-31	Revenue	92523000	Revenue: 92523000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

25% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Year over year	No prior comparable period	Revenue: 80911000 Open source
20122012-12-31	Year over year	-81.1%	Revenue: 15254000 Open source Revenue: 80911000 Open source
20132013-12-31	Year over year	275.2%	Revenue: 57230000 Open source Revenue: 15254000 Open source
20142014-12-31	Year over year	-74.4%	Revenue: 14632000 Open source Revenue: 57230000 Open source
20152015-12-31	Year over year	23.7%	Revenue: 18097000 Open source Revenue: 14632000 Open source
20162016-12-31	Year over year	53.5%	Revenue: 27771000 Open source Revenue: 18097000 Open source
20172017-12-31	Year over year	-51.5%	Revenue: 13481000 Open source Revenue: 27771000 Open source
20182018-12-31	Year over year	3.8%	Revenue: 13991000 Open source Revenue: 13481000 Open source
20192019-12-31	Year over year	428.9%	Revenue: 73993000 Open source Revenue: 13991000 Open source
20202020-12-31	Year over year	25%	Revenue: 92523000 Open source Revenue: 73993000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -180.8% 2020

Net margin -179.4% 2020

Free cash flow margin -145.4% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Operating margin	47.7%	Operating Income: 38556000 Open source Revenue: 80911000 Open source
20122012-12-31	Operating margin	-189.4%	Operating Income: -28889000 Open source Revenue: 15254000 Open source
20132013-12-31	Operating margin	12.1%	Operating Income: 6952000 Open source Revenue: 57230000 Open source
20142014-12-31	Operating margin	-379.1%	Operating Income: -55464000 Open source Revenue: 14632000 Open source
20152015-12-31	Operating margin	-336.4%	Operating Income: -60879000 Open source Revenue: 18097000 Open source
20162016-12-31	Operating margin	-238%	Operating Income: -66106000 Open source Revenue: 27771000 Open source
20172017-12-31	Operating margin	-815.8%	Operating Income: -109983000 Open source Revenue: 13481000 Open source
20182018-12-31	Operating margin	-889.2%	Operating Income: -124414000 Open source Revenue: 13991000 Open source
20192019-12-31	Operating margin	-184.4%	Operating Income: -136445000 Open source Revenue: 73993000 Open source
20202020-12-31	Operating margin	-180.8%	Operating Income: -167306000 Open source Revenue: 92523000 Open source
20112011-12-31	Net margin	44.8%	Net Income: 36266000 Open source Revenue: 80911000 Open source
20122012-12-31	Net margin	-213.6%	Net Income: -32582000 Open source Revenue: 15254000 Open source
20132013-12-31	Net margin	-38.3%	Net Income: -21898000 Open source Revenue: 57230000 Open source
20142014-12-31	Net margin	-350.3%	Net Income: -51259000 Open source Revenue: 14632000 Open source
20152015-12-31	Net margin	-353.1%	Net Income: -63894000 Open source Revenue: 18097000 Open source
20162016-12-31	Net margin	-205.3%	Net Income: -57014000 Open source Revenue: 27771000 Open source
20172017-12-31	Net margin	-804.5%	Net Income: -108454000 Open source Revenue: 13481000 Open source
20182018-12-31	Net margin	-849.6%	Net Income: -118871000 Open source Revenue: 13991000 Open source
20192019-12-31	Net margin	-168.7%	Net Income: -124858000 Open source Revenue: 73993000 Open source
20202020-12-31	Net margin	-179.4%	Net Income: -166030000 Open source Revenue: 92523000 Open source
20112011-12-31	Free cash flow margin	11.2%	Revenue: 80911000 Open source Operating Cash Flow: 9056000 Open source Capital Expenditure: 27000 Open source
20122012-12-31	Free cash flow margin	-257.8%	Revenue: 15254000 Open source Operating Cash Flow: -38884000 Open source Capital Expenditure: 441000 Open source
20132013-12-31	Free cash flow margin	-34.9%	Revenue: 57230000 Open source Operating Cash Flow: -19650000 Open source Capital Expenditure: 307000 Open source
20142014-12-31	Free cash flow margin	-367.2%	Revenue: 14632000 Open source Operating Cash Flow: -53220000 Open source Capital Expenditure: 514000 Open source
20152015-12-31	Free cash flow margin	-249.6%	Revenue: 18097000 Open source Operating Cash Flow: -44211000 Open source Capital Expenditure: 959000 Open source
20162016-12-31	Free cash flow margin	-172.6%	Revenue: 27771000 Open source Operating Cash Flow: -44545000 Open source Capital Expenditure: 3380000 Open source
20172017-12-31	Free cash flow margin	-600.4%	Revenue: 13481000 Open source Operating Cash Flow: -76544000 Open source Capital Expenditure: 4396000 Open source
20182018-12-31	Free cash flow margin	-695.4%	Revenue: 13991000 Open source Operating Cash Flow: -94706000 Open source Capital Expenditure: 2590000 Open source
20192019-12-31	Free cash flow margin	-131.2%	Revenue: 73993000 Open source Operating Cash Flow: -93804000 Open source Capital Expenditure: 3287000 Open source
20202020-12-31	Free cash flow margin	-145.4%	Revenue: 92523000 Open source Operating Cash Flow: -130327000 Open source Capital Expenditure: 4203000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -130.3M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Operating cash flow	9056000	Operating Cash Flow: 9056000 Open source
20122012-12-31	Operating cash flow	-38884000	Operating Cash Flow: -38884000 Open source
20132013-12-31	Operating cash flow	-19650000	Operating Cash Flow: -19650000 Open source
20142014-12-31	Operating cash flow	-53220000	Operating Cash Flow: -53220000 Open source
20152015-12-31	Operating cash flow	-44211000	Operating Cash Flow: -44211000 Open source
20162016-12-31	Operating cash flow	-44545000	Operating Cash Flow: -44545000 Open source
20172017-12-31	Operating cash flow	-76544000	Operating Cash Flow: -76544000 Open source
20182018-12-31	Operating cash flow	-94706000	Operating Cash Flow: -94706000 Open source
20192019-12-31	Operating cash flow	-93804000	Operating Cash Flow: -93804000 Open source
20202020-12-31	Operating cash flow	-130327000	Operating Cash Flow: -130327000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -134.5M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Free cash flow	9029000	Operating Cash Flow: 9056000 Open source Capital Expenditure: 27000 Open source
20122012-12-31	Free cash flow	-39325000	Operating Cash Flow: -38884000 Open source Capital Expenditure: 441000 Open source
20132013-12-31	Free cash flow	-19957000	Operating Cash Flow: -19650000 Open source Capital Expenditure: 307000 Open source
20142014-12-31	Free cash flow	-53734000	Operating Cash Flow: -53220000 Open source Capital Expenditure: 514000 Open source
20152015-12-31	Free cash flow	-45170000	Operating Cash Flow: -44211000 Open source Capital Expenditure: 959000 Open source
20162016-12-31	Free cash flow	-47925000	Operating Cash Flow: -44545000 Open source Capital Expenditure: 3380000 Open source
20172017-12-31	Free cash flow	-80940000	Operating Cash Flow: -76544000 Open source Capital Expenditure: 4396000 Open source
20182018-12-31	Free cash flow	-97296000	Operating Cash Flow: -94706000 Open source Capital Expenditure: 2590000 Open source
20192019-12-31	Free cash flow	-97091000	Operating Cash Flow: -93804000 Open source Capital Expenditure: 3287000 Open source
20202020-12-31	Free cash flow	-134530000	Operating Cash Flow: -130327000 Open source Capital Expenditure: 4203000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8.3% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Liabilities / assets	88%	Total Liabilities: 64931000 Open source Total Assets: 73789000 Open source
20122012-12-31	Liabilities / assets	145.4%	Total Liabilities: 71575000 Open source Total Assets: 49212000 Open source
20132013-12-31	Liabilities / assets	53.3%	Total Liabilities: 65920000 Open source Total Assets: 123732000 Open source
20142014-12-31	Liabilities / assets	16.1%	Total Liabilities: 30011000 Open source Total Assets: 186296000 Open source
20152015-12-31	Liabilities / assets	25.3%	Total Liabilities: 37074000 Open source Total Assets: 146337000 Open source
20162016-12-31	Liabilities / assets	8.9%	Total Liabilities: 22050000 Open source Total Assets: 247647000 Open source
20172017-12-31	Liabilities / assets	6.2%	Total Liabilities: 23960000 Open source Total Assets: 389177000 Open source
20182018-12-31	Liabilities / assets	7.2%	Total Liabilities: 22784000 Open source Total Assets: 314821000 Open source
20192019-12-31	Liabilities / assets	11%	Total Liabilities: 55430000 Open source Total Assets: 504906000 Open source
20202020-12-31	Liabilities / assets	8.3%	Total Liabilities: 77230000 Open source Total Assets: 932337000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

14.85× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Current assets / current liabilities	2.84×	Current Assets: 67741000 Open source Current Liabilities: 23853000 Open source
20122012-12-31	Current assets / current liabilities	1.13×	Current Assets: 43861000 Open source Current Liabilities: 38802000 Open source
20132013-12-31	Current assets / current liabilities	4.37×	Current Assets: 119022000 Open source Current Liabilities: 27210000 Open source
20142014-12-31	Current assets / current liabilities	19.7×	Current Assets: 182307000 Open source Current Liabilities: 9253000 Open source
20152015-12-31	Current assets / current liabilities	7.66×	Current Assets: 110933000 Open source Current Liabilities: 14491000 Open source
20162016-12-31	Current assets / current liabilities	9.09×	Current Assets: 146786000 Open source Current Liabilities: 16149000 Open source
20172017-12-31	Current assets / current liabilities	17.03×	Current Assets: 285243000 Open source Current Liabilities: 16745000 Open source
20182018-12-31	Current assets / current liabilities	16.18×	Current Assets: 306013000 Open source Current Liabilities: 18912000 Open source
20192019-12-31	Current assets / current liabilities	13.48×	Current Assets: 449916000 Open source Current Liabilities: 33373000 Open source
20202020-12-31	Current assets / current liabilities	14.85×	Current Assets: 893269000 Open source Current Liabilities: 60163000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2011 2011-01-01 – 2011-12-31	USD 36.27 million Exact value Exact value: 36266000 USD 2011-01-01 – 2011-12-31: 36266000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2011-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: 36266000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: 36266000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000104746914002530/xlrn-20131231.xml#905109 Filing: 000104746914002530 The citation records this snapshot. The page link may show a newer release later.	USD 9.06 million Exact value Exact value: 9056000 USD 2011-01-01 – 2011-12-31: 9056000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2011-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: 9056000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9056000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000104746914002530/xlrn-20131231.xml#911781 Filing: 000104746914002530 The citation records this snapshot. The page link may show a newer release later.	USD 27,000 Exact value Exact value: 27000 USD 2011-01-01 – 2011-12-31: 27000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2011-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 27000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 27000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000104746914002530/xlrn-20131231.xml#912168 Filing: 000104746914002530 The citation records this snapshot. The page link may show a newer release later.	USD 9.03 million Calculation and evidence 9056000 − 27000 USD Exact free cash flow: 9029000 USD 2011-01-01 – 2011-12-31: 9056000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 27000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2011-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: 9029000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9056000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000104746914002530/xlrn-20131231.xml#911781 Filing: 000104746914002530 Input fundies:CapitalExpenditure: 27000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000104746914002530/xlrn-20131231.xml#912168 Filing: 000104746914002530 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 32.58 million Exact value Exact value: -32582000 USD 2012-01-01 – 2012-12-31: -32582000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2012-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -32582000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32582000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060015000009/xlrn-20141231.xml#355632 Filing: 000128060015000009 The citation records this snapshot. The page link may show a newer release later.	−USD 38.88 million Exact value Exact value: -38884000 USD 2012-01-01 – 2012-12-31: -38884000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2012-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -38884000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -38884000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060015000009/xlrn-20141231.xml#354876 Filing: 000128060015000009 The citation records this snapshot. The page link may show a newer release later.	USD 441,000 Exact value Exact value: 441000 USD 2012-01-01 – 2012-12-31: 441000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2012-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 441000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 441000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060015000009/xlrn-20141231.xml#368929 Filing: 000128060015000009 The citation records this snapshot. The page link may show a newer release later.	−USD 39.33 million Calculation and evidence -38884000 − 441000 USD Exact free cash flow: -39325000 USD 2012-01-01 – 2012-12-31: -38884000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 441000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2012-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -39325000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38884000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060015000009/xlrn-20141231.xml#354876 Filing: 000128060015000009 Input fundies:CapitalExpenditure: 441000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060015000009/xlrn-20141231.xml#368929 Filing: 000128060015000009 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 21.9 million Exact value Exact value: -21898000 USD 2013-01-01 – 2013-12-31: -21898000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2013-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -21898000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21898000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060016000072/xlrn-20151231.xml#362096 Filing: 000128060016000072 The citation records this snapshot. The page link may show a newer release later.	−USD 19.65 million Exact value Exact value: -19650000 USD 2013-01-01 – 2013-12-31: -19650000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2013-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -19650000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19650000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060016000072/xlrn-20151231.xml#361460 Filing: 000128060016000072 The citation records this snapshot. The page link may show a newer release later.	USD 307,000 Exact value Exact value: 307000 USD 2013-01-01 – 2013-12-31: 307000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2013-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 307000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 307000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060016000072/xlrn-20151231.xml#377205 Filing: 000128060016000072 The citation records this snapshot. The page link may show a newer release later.	−USD 19.96 million Calculation and evidence -19650000 − 307000 USD Exact free cash flow: -19957000 USD 2013-01-01 – 2013-12-31: -19650000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 307000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2013-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -19957000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19650000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060016000072/xlrn-20151231.xml#361460 Filing: 000128060016000072 Input fundies:CapitalExpenditure: 307000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060016000072/xlrn-20151231.xml#377205 Filing: 000128060016000072 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 51.26 million Exact value Exact value: -51259000 USD 2014-01-01 – 2014-12-31: -51259000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2014-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -51259000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51259000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060017000008/xlrn-20161231.xml#351245 Filing: 000128060017000008 The citation records this snapshot. The page link may show a newer release later.	−USD 53.22 million Exact value Exact value: -53220000 USD 2014-01-01 – 2014-12-31: -53220000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2014-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -53220000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -53220000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060017000008/xlrn-20161231.xml#350609 Filing: 000128060017000008 The citation records this snapshot. The page link may show a newer release later.	USD 514,000 Exact value Exact value: 514000 USD 2014-01-01 – 2014-12-31: 514000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2014-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 514000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 514000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060017000008/xlrn-20161231.xml#364728 Filing: 000128060017000008 The citation records this snapshot. The page link may show a newer release later.	−USD 53.73 million Calculation and evidence -53220000 − 514000 USD Exact free cash flow: -53734000 USD 2014-01-01 – 2014-12-31: -53220000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 514000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2014-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -53734000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -53220000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060017000008/xlrn-20161231.xml#350609 Filing: 000128060017000008 Input fundies:CapitalExpenditure: 514000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060017000008/xlrn-20161231.xml#364728 Filing: 000128060017000008 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 63.89 million Exact value Exact value: -63894000 USD 2015-01-01 – 2015-12-31: -63894000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2015-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -63894000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -63894000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060018000016/xlrn-20171231.xml#316226 Filing: 000128060018000016 The citation records this snapshot. The page link may show a newer release later.	−USD 44.21 million Exact value Exact value: -44211000 USD 2015-01-01 – 2015-12-31: -44211000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2015-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -44211000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44211000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060018000016/xlrn-20171231.xml#315590 Filing: 000128060018000016 The citation records this snapshot. The page link may show a newer release later.	USD 959,000 Exact value Exact value: 959000 USD 2015-01-01 – 2015-12-31: 959000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2015-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 959000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 959000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060018000016/xlrn-20171231.xml#331341 Filing: 000128060018000016 The citation records this snapshot. The page link may show a newer release later.	−USD 45.17 million Calculation and evidence -44211000 − 959000 USD Exact free cash flow: -45170000 USD 2015-01-01 – 2015-12-31: -44211000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 959000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2015-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -45170000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44211000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060018000016/xlrn-20171231.xml#315590 Filing: 000128060018000016 Input fundies:CapitalExpenditure: 959000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060018000016/xlrn-20171231.xml#331341 Filing: 000128060018000016 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 57.01 million Exact value Exact value: -57014000 USD 2016-01-01 – 2016-12-31: -57014000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2016-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -57014000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57014000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060019000012/xlrn-20181231.xml#311865 Filing: 000128060019000012 The citation records this snapshot. The page link may show a newer release later.	−USD 44.55 million Exact value Exact value: -44545000 USD 2016-01-01 – 2016-12-31: -44545000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2016-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -44545000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -44545000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060019000012/xlrn-20181231.xml#311229 Filing: 000128060019000012 The citation records this snapshot. The page link may show a newer release later.	USD 3.38 million Exact value Exact value: 3380000 USD 2016-01-01 – 2016-12-31: 3380000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2016-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 3380000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3380000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060019000012/xlrn-20181231.xml#327591 Filing: 000128060019000012 The citation records this snapshot. The page link may show a newer release later.	−USD 47.93 million Calculation and evidence -44545000 − 3380000 USD Exact free cash flow: -47925000 USD 2016-01-01 – 2016-12-31: -44545000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3380000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2016-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -47925000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -44545000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060019000012/xlrn-20181231.xml#311229 Filing: 000128060019000012 Input fundies:CapitalExpenditure: 3380000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060019000012/xlrn-20181231.xml#327591 Filing: 000128060019000012 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 108.45 million Exact value Exact value: -108454000 USD 2017-01-01 – 2017-12-31: -108454000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2017-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -108454000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108454000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060020000012/xlrn-20191231x10k.htm#1449118 Filing: 000128060020000012 The citation records this snapshot. The page link may show a newer release later.	−USD 76.54 million Exact value Exact value: -76544000 USD 2017-01-01 – 2017-12-31: -76544000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2017-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -76544000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76544000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060020000012/xlrn-20191231x10k.htm#1482184 Filing: 000128060020000012 The citation records this snapshot. The page link may show a newer release later.	USD 4.4 million Exact value Exact value: 4396000 USD 2017-01-01 – 2017-12-31: 4396000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2017-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 4396000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4396000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060020000012/xlrn-20191231x10k.htm#1492509 Filing: 000128060020000012 The citation records this snapshot. The page link may show a newer release later.	−USD 80.94 million Calculation and evidence -76544000 − 4396000 USD Exact free cash flow: -80940000 USD 2017-01-01 – 2017-12-31: -76544000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4396000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2017-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -80940000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76544000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060020000012/xlrn-20191231x10k.htm#1482184 Filing: 000128060020000012 Input fundies:CapitalExpenditure: 4396000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060020000012/xlrn-20191231x10k.htm#1492509 Filing: 000128060020000012 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 118.87 million Exact value Exact value: -118871000 USD 2018-01-01 – 2018-12-31: -118871000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2018-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -118871000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -118871000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1293194 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 94.71 million Exact value Exact value: -94706000 USD 2018-01-01 – 2018-12-31: -94706000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2018-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -94706000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -94706000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1331240 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	USD 2.59 million Exact value Exact value: 2590000 USD 2018-01-01 – 2018-12-31: 2590000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2018-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 2590000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2590000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1341893 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 97.3 million Calculation and evidence -94706000 − 2590000 USD Exact free cash flow: -97296000 USD 2018-01-01 – 2018-12-31: -94706000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2590000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2018-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -97296000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -94706000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1331240 Filing: 000128060021000017 Input fundies:CapitalExpenditure: 2590000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1341893 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 124.86 million Exact value Exact value: -124858000 USD 2019-01-01 – 2019-12-31: -124858000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2019-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -124858000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -124858000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1292024 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 93.8 million Exact value Exact value: -93804000 USD 2019-01-01 – 2019-12-31: -93804000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2019-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -93804000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93804000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1330190 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	USD 3.29 million Exact value Exact value: 3287000 USD 2019-01-01 – 2019-12-31: 3287000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2019-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 3287000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3287000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1340911 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 97.09 million Calculation and evidence -93804000 − 3287000 USD Exact free cash flow: -97091000 USD 2019-01-01 – 2019-12-31: -93804000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 3287000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2019-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -97091000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93804000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1330190 Filing: 000128060021000017 Input fundies:CapitalExpenditure: 3287000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1340911 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 166.03 million Exact value Exact value: -166030000 USD 2020-01-01 – 2020-12-31: -166030000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Net Income: -166030000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -166030000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1290854 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 130.33 million Exact value Exact value: -130327000 USD 2020-01-01 – 2020-12-31: -130327000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Operating Cash Flow: -130327000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -130327000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1329139 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	USD 4.2 million Exact value Exact value: 4203000 USD 2020-01-01 – 2020-12-31: 4203000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Capital Expenditure: 4203000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4203000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1339929 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.	−USD 134.53 million Calculation and evidence -130327000 − 4203000 USD Exact free cash flow: -134530000 USD 2020-01-01 – 2020-12-31: -130327000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 4203000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ACCELERON PHARMA INC. · 2020-12-31 ACCELERON PHARMA INC. (edgar:1280600) Free cash flow: -134530000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T00:05:27Z Snapshot: 041c637a46266cac7e3ae892861f7147cc559d91314499f1576baeaf4e66cab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1280600?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -130327000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1329139 Filing: 000128060021000017 Input fundies:CapitalExpenditure: 4203000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#1339929 Filing: 000128060021000017 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

86 filings · 2,641 latest values · 2,641 originally reported values

Dataset published 2026-11-03. Source filing dates and reporting periods are shown separately.

Identifiers: 0001280600, 1280600, XLRN, edgar:1280600

Also known as ACCELERON PHARMA INC, ACCELERON PHARMA INC., ACCELERON PHARMA INC, ACCELERON PHARMA INC.

ACCELERON PHARMA INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation